Cell and Gene Therapy Today—May 21, 2026

This week’s Gene and Cell Therapy update highlights regulatory progress, pivotal clinical data, AI-enabled vector innovation, and expanding partnerships across genetic and cell therapy platforms.

In Today’s Newsletter

Dive deeper

🧬 Vyjuvek gains UK MHRA approval [1] [UK • 18 May 2026]

https://www.europeanpharmaceuticalreview.com/krystal-biotech-wins-mhra-approval-for-genetic-medicine-vyjuvek/2135475.article
Context: MHRA approved Vyjuvek (Krystal Biotech; beremagene geperpavec) for wounds in dystrophic epidermolysis bullosa.
Key point: The gel-based genetic medicine copies the faulty gene into wound cells; a 31-patient study reported complete healing in 67% of treated wounds at six months versus 22% with placebo.
Implication: May influence prescriber choice and payer reviews pending full data.

🧠 AI-designed vectors enrich brain delivery in mice [2] [19 May 2026]

https://www.drugtargetreview.com/ai-designed-viral-vectors-achieve-50-fold-brain-enrichment-over-aav9/2135485.article
Context: WhiteLab Genomics reported AI-designed vectors with about 50-fold higher brain DNA enrichment than AAV9 after IV injection in mice.
Key point: The ALFRED-designed vectors were undetectable in liver in the reported preclinical data and were presented at ASGCT.
Implication: Signals pipeline investment and modality expansion.

💪 RGX-202 hits Duchenne Phase 3 primary endpoint [3] [US • 14 May 2026]

https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-reports-first-quarter-2026-financial-results-and
Context: REGENXBIO said RGX-202 achieved the primary endpoint in pivotal Phase 3 AFFINITY DUCHENNE with high statistical significance.
Key point: The company reported Week 12 microdystrophin expression data, interim safety, interim functional data, and plans for potential accelerated approval in 2027.
Implication: May influence prescriber choice and payer reviews pending full data.

🫁 BEAM-302 AATD data presented at ATS [4] [US • 18 May 2026]

https://investors.beamtx.com/news-releases/news-release-details/beam-therapeutics-presents-recently-reported-topline-clinical
Context: Beam Therapeutics presented BEAM-302 Phase 1/2 data in alpha-1 antitrypsin deficiency at ATS 2026.
Key point: The update included single-dose cohort safety, durability, and human neutrophil elastase activity data from a 29-patient cutoff.
Implication: May influence prescriber choice and payer reviews pending full data.

🧫 GC Cell doses first AB-201 patient [5] [South Korea • 19 May 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=31708
Context: GC Cell said the first patient was dosed in an advanced regenerative medicine study of AB-201.
Key point: AB-201 is a HER2-targeted allogeneic CAR-NK therapy being studied in advanced HER2-positive gastric and gastroesophageal junction cancers.
Implication: Signals pipeline investment and modality expansion.

🤝 Regeneron and Parabilis partner on Helicon conjugates [6] [US • 18 May 2026]

https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-strategic-collaboration-parabilis-medicines
Context: Regeneron and Parabilis Medicines announced a multi-target collaboration using Parabilis’ Helicon peptide platform.
Key point: The deal includes $125 million upfront and equity commitment, with potential milestones of up to about $2.2 billion plus royalties.
Implication: Signals pipeline investment and modality expansion.

Why It Matters

Genetic medicine approvals are moving into rare dermatology, with Vyjuvek adding a UK option for dystrophic epidermolysis bullosa.
CNS delivery remains a key bottleneck, and WhiteLab’s mouse data point to AI-guided vector design as a possible route around invasive administration.
Duchenne gene therapy competition continues to intensify as REGENXBIO advances RGX-202 toward a potential accelerated approval path.
Base editing in AATD is moving closer to pivotal development, with Beam planning an expanded cohort after FDA feedback.
Cell therapy and peptide-conjugate platforms are expanding beyond traditional oncology and antibody-drug conjugate playbooks.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 See the full Cell and Gene Therapy archive on our research hub page.

FAQ

What is Vyjuvek from Krystal Biotech?

Vyjuvek (beremagene geperpavec) is a gel-based genetic medicine for dystrophic epidermolysis bullosa wounds. MHRA approved it for UK patients. [1]

What did WhiteLab Genomics report for its AI-designed vectors?

WhiteLab Genomics reported preclinical mouse data showing about 50-fold higher brain DNA enrichment than AAV9 after IV dosing, with no detectable liver signal. [2]

What is RGX-202 in REGENXBIO’s AFFINITY DUCHENNE study?

RGX-202 is REGENXBIO’s investigational microdystrophin gene therapy for Duchenne muscular dystrophy. The company said the pivotal Phase 3 study met its primary endpoint. [3]

What is BEAM-302 targeting?

BEAM-302 is Beam Therapeutics’ base-editing candidate for alpha-1 antitrypsin deficiency. Beam said FDA feedback supports an accelerated approval pathway. [4]

What is GC Cell’s AB-201?

AB-201 is a HER2-targeted allogeneic CAR-NK therapy for HER2-positive solid tumors. The first patient was dosed in gastric and gastroesophageal junction cancer. [5]

What are Antibody-Helicon Conjugates?

Regeneron and Parabilis describe them as antibody-linked Helicon peptide therapeutics designed to target intracellular proteins, including historically difficult targets. [6]

Entities / Keywords

Krystal Biotech, Vyjuvek, beremagene geperpavec, dystrophic epidermolysis bullosa, DEB, MHRA
WhiteLab Genomics, ALFRED, AI-designed viral vectors, AAV9, blood-brain barrier, ASGCT
REGENXBIO, RGX-202, AFFINITY DUCHENNE, Duchenne muscular dystrophy, microdystrophin
Beam Therapeutics, BEAM-302, alpha-1 antitrypsin deficiency, AATD, base editing, ATS 2026
GC Cell, AB-201, HER2, CAR-NK, gastric cancer, gastroesophageal junction cancer
Regeneron, Parabilis Medicines, Helicon, Antibody-Helicon Conjugates, AHCs, VelocImmune